EF Hutton Acquisition Co. I Upgrades UroGen Pharma (NASDAQ:URGN) to “Strong-Buy”

EF Hutton Acquisition Co. I upgraded shares of UroGen Pharma (NASDAQ:URGN) to a strong-buy rating in a research note published on Monday morning, Zacks.com reports.

A number of other brokerages also recently issued reports on URGN. HC Wainwright reaffirmed a “buy” rating and set a $60.00 price target on shares of UroGen Pharma in a report on Thursday, October 3rd. Guggenheim assumed coverage on UroGen Pharma in a report on Thursday, August 22nd. They issued a “buy” rating and a $40.00 price target for the company. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, UroGen Pharma currently has an average rating of “Buy” and a consensus target price of $48.38.

UroGen Pharma Stock Up 2.8 %

URGN stock opened at $12.60 on Monday. UroGen Pharma has a fifty-two week low of $10.60 and a fifty-two week high of $20.70. The company’s 50 day moving average price is $13.52 and its 200 day moving average price is $14.37. The company has a debt-to-equity ratio of 3.23, a quick ratio of 7.93 and a current ratio of 8.15. The firm has a market capitalization of $295.52 million, a price-to-earnings ratio of -3.71 and a beta of 1.11.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.09). The firm had revenue of $21.85 million for the quarter, compared to analyst estimates of $23.69 million. On average, equities research analysts anticipate that UroGen Pharma will post -3.49 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Marshall Wace LLP acquired a new stake in shares of UroGen Pharma in the second quarter valued at approximately $719,000. Price T Rowe Associates Inc. MD acquired a new position in shares of UroGen Pharma in the 1st quarter valued at $4,008,000. Millennium Management LLC raised its position in UroGen Pharma by 2,672.0% in the 2nd quarter. Millennium Management LLC now owns 1,160,899 shares of the company’s stock valued at $19,480,000 after purchasing an additional 1,119,019 shares during the last quarter. Point72 Asset Management L.P. raised its position in UroGen Pharma by 120.3% in the 2nd quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company’s stock valued at $41,099,000 after purchasing an additional 1,337,257 shares during the last quarter. Finally, Wesbanco Bank Inc. acquired a new stake in UroGen Pharma during the 3rd quarter worth $945,000. Institutional investors and hedge funds own 91.29% of the company’s stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.